<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831385</url>
  </required_header>
  <id_info>
    <org_study_id>Version Date 15 April 2021</org_study_id>
    <nct_id>NCT04831385</nct_id>
  </id_info>
  <brief_title>The Impact of Cognitive Behavioral Therapy for Insomnia (CBT-I) on Glycemic Control in Older Type 2 Diabetes (T2D) Comorbid With Insomnia</brief_title>
  <official_title>The Impact of Cognitive Behavioral Therapy for Insomnia (CBT-I) on Glycemic Control in Older Type 2 Diabetes (T2D) Comorbid With Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a RCT aiming to use CBT-I as intervention, compared to usual care as control,&#xD;
      to elucidate the effect of CBT-I on glycemic control, sleep quality, psychological outcomes,&#xD;
      and cognitive function in Hong Kong Chinese older T2D comorbid with insomnia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be changes in glycemic control, as measured by HbA1c, from baseline.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>CBT-i</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (Usual Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioural Therapy</intervention_name>
    <description>CBT is a first line therapy for insomnia</description>
    <arm_group_label>CBT-i</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥65 years;&#xD;
&#xD;
          2. T2D with suboptimal glycemic control defined as HbA1c 7.5-10%;&#xD;
&#xD;
          3. Chinese ethnicity;&#xD;
&#xD;
          4. Comorbid with insomnia having ISI score &gt;14;&#xD;
&#xD;
          5. Able and willing to give informed written consen&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Cognitive impairment (HK-MoCA score of ≤22);&#xD;
&#xD;
          2. Depression (GDS-15 score &gt;8) and other psychiatric disorders e.g. generalized anxiety&#xD;
             disorder, restless leg syndrome, schizophrenia to be elucidated by history from&#xD;
             research nurse and questionnaires;&#xD;
&#xD;
          3. OSA as defined as apnoea-hypopnoea index (AHI) ≥15 events per night;&#xD;
&#xD;
          4. Benign prostatic hypertrophy by history and/or elevated PSA and any other chronic&#xD;
             medical condition that is likely to affect sleep e.g. chronic pain;&#xD;
&#xD;
          5. Concurrent use of hypnotic drugs, psychotic medications and any drugs that are known&#xD;
             to affect sleep;&#xD;
&#xD;
          6. Cerebrovascular accidents, vascular dementia, or any condition that are known to&#xD;
             affect cognitive function;&#xD;
&#xD;
          7. Shift workers;&#xD;
&#xD;
          8. Haemoglobinopathies, renal failure, need of regular blood transfusion or any other&#xD;
             conditions which will affect the validity of HbA1c in measurement of glycemia;&#xD;
&#xD;
          9. Any condition, as judged by the investigators, as ineligible to participate in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Alice Pik Shan KONG</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

